BR0206917A - Uso de antagonistas de mglur5 para o tratamento de condições prurìticas - Google Patents
Uso de antagonistas de mglur5 para o tratamento de condições prurìticasInfo
- Publication number
- BR0206917A BR0206917A BR0206917-2A BR0206917A BR0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A BR 0206917 A BR0206917 A BR 0206917A
- Authority
- BR
- Brazil
- Prior art keywords
- mglur5 antagonists
- pruritic conditions
- treat
- treat pruritic
- conditions
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 230000001823 pruritic effect Effects 0.000 title abstract 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103045.1A GB0103045D0 (en) | 2001-02-07 | 2001-02-07 | Organic Compounds |
| PCT/EP2002/001250 WO2002062323A2 (en) | 2001-02-07 | 2002-02-06 | Use of mglur5 antagonists for the treatment of pruritic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206917A true BR0206917A (pt) | 2004-02-03 |
Family
ID=9908300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206917-2A BR0206917A (pt) | 2001-02-07 | 2002-02-06 | Uso de antagonistas de mglur5 para o tratamento de condições prurìticas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040106582A1 (enExample) |
| EP (1) | EP1359905B1 (enExample) |
| JP (2) | JP2004517947A (enExample) |
| CN (1) | CN1253151C (enExample) |
| AT (1) | ATE333869T1 (enExample) |
| AU (1) | AU2002231777A1 (enExample) |
| BR (1) | BR0206917A (enExample) |
| CA (1) | CA2433409C (enExample) |
| DE (1) | DE60213365T2 (enExample) |
| ES (1) | ES2271229T3 (enExample) |
| GB (1) | GB0103045D0 (enExample) |
| PT (1) | PT1359905E (enExample) |
| WO (1) | WO2002062323A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
| GB0322612D0 (en) * | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
| EP1677790A1 (en) * | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes ii |
| EP1677789A1 (en) * | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes i |
| EP1677788A1 (en) * | 2003-10-31 | 2006-07-12 | AstraZeneca AB | Alkynes iii |
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| CA2881638A1 (en) | 2012-08-30 | 2014-03-06 | Nippon Shinyaku Co., Ltd. | Pyridine derivative and medicine |
| JP6603334B2 (ja) * | 2015-06-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | エチニル誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013744B1 (en) * | 1989-12-29 | 1994-09-20 | Allegran Inc | Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity |
| FR2719044B1 (fr) * | 1994-04-26 | 1996-05-31 | Cird Galderma | Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations. |
| US5498795A (en) * | 1994-12-29 | 1996-03-12 | Allergan, Inc. | Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
| US5534641A (en) * | 1994-12-29 | 1996-07-09 | Allergan | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6774138B2 (en) * | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
-
2001
- 2001-02-07 GB GBGB0103045.1A patent/GB0103045D0/en not_active Ceased
-
2002
- 2002-02-06 AT AT02711840T patent/ATE333869T1/de active
- 2002-02-06 US US10/466,183 patent/US20040106582A1/en not_active Abandoned
- 2002-02-06 CN CNB028046307A patent/CN1253151C/zh not_active Expired - Fee Related
- 2002-02-06 PT PT02711840T patent/PT1359905E/pt unknown
- 2002-02-06 CA CA2433409A patent/CA2433409C/en not_active Expired - Fee Related
- 2002-02-06 JP JP2002562330A patent/JP2004517947A/ja not_active Withdrawn
- 2002-02-06 BR BR0206917-2A patent/BR0206917A/pt not_active Application Discontinuation
- 2002-02-06 AU AU2002231777A patent/AU2002231777A1/en not_active Abandoned
- 2002-02-06 WO PCT/EP2002/001250 patent/WO2002062323A2/en not_active Ceased
- 2002-02-06 ES ES02711840T patent/ES2271229T3/es not_active Expired - Lifetime
- 2002-02-06 DE DE60213365T patent/DE60213365T2/de not_active Expired - Lifetime
- 2002-02-06 EP EP02711840A patent/EP1359905B1/en not_active Expired - Lifetime
-
2007
- 2007-06-26 US US11/823,310 patent/US20070265279A1/en not_active Abandoned
-
2012
- 2012-04-03 JP JP2012084772A patent/JP2012131829A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1253151C (zh) | 2006-04-26 |
| ATE333869T1 (de) | 2006-08-15 |
| DE60213365D1 (de) | 2006-09-07 |
| PT1359905E (pt) | 2006-11-30 |
| JP2004517947A (ja) | 2004-06-17 |
| CA2433409C (en) | 2010-04-20 |
| CN1535143A (zh) | 2004-10-06 |
| DE60213365T2 (de) | 2007-08-09 |
| WO2002062323A3 (en) | 2003-03-20 |
| US20040106582A1 (en) | 2004-06-03 |
| EP1359905B1 (en) | 2006-07-26 |
| CA2433409A1 (en) | 2002-08-15 |
| AU2002231777A1 (en) | 2002-08-19 |
| EP1359905A2 (en) | 2003-11-12 |
| ES2271229T3 (es) | 2007-04-16 |
| GB0103045D0 (en) | 2001-03-21 |
| JP2012131829A (ja) | 2012-07-12 |
| WO2002062323A2 (en) | 2002-08-15 |
| US20070265279A1 (en) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69732868D1 (de) | Mittel gegen Juckreiz | |
| BR0016878A (pt) | Inibidores tricìclicos de cinases protéicas | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| CY1115124T1 (el) | Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης | |
| ATE420879T1 (de) | Indolizine als kinaseproteinhemmer | |
| BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
| BR0212924A (pt) | Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma | |
| EA200300566A1 (ru) | Применение cci-779 в качестве противоопухолевого средства | |
| CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
| CL2007002389A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas. | |
| DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| UA85394C2 (ru) | Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ | |
| UY27606A1 (es) | Inhibidores de la fosfarasa | |
| ATE363531T1 (de) | Claudin polypeptide | |
| DK1373220T3 (da) | Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion | |
| BR0206917A (pt) | Uso de antagonistas de mglur5 para o tratamento de condições prurìticas | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| DE60329326D1 (de) | Tace inhibitoren | |
| BR0209883A (pt) | Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco | |
| TR200102448T2 (tr) | COPD tedavisi için kontrollu salma formülasyonu. | |
| DE60224667D1 (de) | Perylenequinonen zur anwendung als sonosensitizer | |
| SE0302361D0 (sv) | Inhibering av upptagning av monoamin | |
| ATE410235T1 (de) | Behandlung von ballastwasser | |
| ATE267194T1 (de) | Medikamente geeignet zur behandlung von proliferativen erkrankungen | |
| DK1521752T3 (da) | Makrocykliske forbindelser til behandling af cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |